Market Report Source

Overview

The highly dynamic cancer market is creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. Resultantly, cancer innovatives are not only the fastest growing segment within the cancer market, but the key drivers of sales growth across the pharmaceutical market as a whole. These innovations will result in high value opportunities to develop newer and more effective therapies, ensuring companies can effectively respond to the increasing prevalence of cancer.

Innovative and Targeted Cancer Therapies provides a detailed insight into both cancer therapeutics and diagnostics, to provide a clear vision of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities, highlighting companies with specialised capabilities in the discovery and the characterization of next-generation drug targets. Use this report to understand how the cancer market is developing, identify areas of unmet medical need and align your product pipeline to achieve clinical and commercial success.

Table of Contents

Innovative and Targeted Cancer Therapies
Executive summary
Cancer innovations are driving pharmaceutical industry growth
Key innovations and technologies
Key therapy areas and applications
Key companies and pipelines
Key trends and implications
Chapter 1 Cancer innovations driving pharma growth
Summary
Introduction
Definitions
Historical performance
Impact of cancer market on industry as a whole
Chapter 2 Key innovations and technologies
Summary
Introduction
Oncology treatment pathways
Chemotherapeutics
Hormonals
Monoclonal antibodies
Targeted therapies
Immunotherapy and vaccines
Leading marketed technologies
Rituxan/ MabThera
Herceptin
Gleevec/ Glivec
Avastin
Eloxatin
Erbitux
Xeloda
Femara
Temodar
Tarceva
Leading new technologies for the future
Kinase inhibitors
Tubulin and microtubule inhibitors
Topoisomerase inhibitors
Cluster of differentiation receptor agonists
DNA polymerase inhibitors
Chapter 3 Key therapy areas and applications
Summary
Introduction
Key therapy areas
Current treatment protocols and unmet needs
Lung cancer
Colorectal cancer
Lymphomas
Leukemia
Breast cancer
Likely future breakthroughs
Alimta
Gardasil
Sutent
Abraxane
Nexavar
Vectibix
Sprycel
Tykerb
Cervarix
MDX-010
Chapter 4 Key companies and pipelines
Summary
Introduction
Leading players
Leading oncology strategies
Lifecycle management growth
Genentech
Roche
Diversification growth
Novartis
Pfizer
Bristol-Myers Squibb
Franchise development growth
Sanofi-Aventis
Schering-Plough
Eli Lilly
New market entry growth
Merck
Bayer Schering
Amgen
GlaxoSmithKline
Chapter 5 Key trends and implications
Summary
Introduction
Future market growth
Market opportunity
Availability of effective treatments
Leading technologies of tomorrow
Key oncology success factors
Lifecycle management
New product development
Index
List of Figures
Figure 1.1: Global cancer innovatives market, 2003-2006
Figure 1.2: Total pharmaceutical market and oncologics sales, 2004-2006
Figure 1.3: Total oncologics and cancer innovatives sales, 2004-2006
Figure 2.4: Leading cancer innovatives products, 2005-2006
Figure 2.5: Rituxan/ MabThera (rituximab), 2003-2006
Figure 2.6: Herceptin (trastuzumab), 2003-2006
Figure 2.7: Gleevec/ Glivec (imatinib), 2003-2006
Figure 2.8: Avastin (bevacizumab), 2003-2006
Figure 2.9: Eloxatin (oxaliplatin), 2003-2006
Figure 2.10: Erbitux (cetuximab), 2003-2006
Figure 2.11: Xeloda (capecitabine), 2003-2006
Figure 2.12: Femara (letrozole), 2003-2006
Figure 2.13: Temodar (temozolomide), 2003-2006
Figure 2.14: Tarceva (erlotinib), 2003-2006
Figure 2.15: Cancer innovations by mode of action, 2007
Figure 3.16: Cancer incidence in US, 2007
Figure 3.17: Cancer deaths in US, 2007
Figure 3.18: Cancer mortality rates in US, 2007
Figure 3.19: New cancer deaths in US, 2007-2012
Figure 3.20: Unmet needs in cancer markets across seven major markets, 2005
Figure 3.21: Alimta (pemetrexed), 2004-2007
Figure 3.22: Gardasil (human papillomavirus vaccine), 2006-2007
Figure 3.23: Sutent (sunitinib), 2006-2007
Figure 3.24: Abraxane (paclitaxel), 2005-2007
Figure 3.25: Nexavar (sorafenib), 2006-2007
Figure 3.26: Vectibix (panitumumab), 2006-2007
Figure 3.27: Sprycel (dasatinib), 2006-2007
Figure 4.28: Leading cancer innovatives companies, 2006-2007
Figure 4.29: Genentech’s cancer innovatives, 2003-2006
Figure 4.30: Roche’s cancer innovatives, 2003-2006
Figure 4.31: Novartis’s cancer innovatives, 2003-2006
Figure 4.32: Pfizer’s cancer innovatives, 2003-2006
Figure 4.33: Bristol-Myers Squibb’s cancer innovatives, 2003-2006
Figure 4.34: Sanofi-Aventis’s cancer innovatives, 2003-2006
Figure 4.35: Schering-Plough’s cancer innovatives, 2003-2006
Figure 4.36: Eli Lilly’s cancer innovatives, 2003-2006
Figure 5.37: Cancer innovatives market forecast, 2003-2011
Figure 5.38: New vs. established cancer innovatives market growth, 2003-2011
Figure 5.39: Leading cancer innovatives drug classes, 2003-2011
Figure 5.40: Leading cancer innovatives drugs, 2011
List of Tables
Table 1.1: Global cancer innovatives market, 2003-2006
Table 2.2: Leading cancer innovatives products, 2003-2006
Table 2.3: Rituxan/ MabThera (rituximab) profile
Table 2.4: Herceptin (trastuzumab) profile
Table 2.5: Gleevec/ Glivec (imatinib) profile
Table 2.6: Avastin (bevacizumab) profile
Table 2.7: Eloxatin (oxaliplatin) profile
Table 2.8: Erbitux (cetuximab) profile
Table 2.9: Xeloda (capecitabine) profile
Table 2.10: Femara (letrozole) profile
Table 2.11: Temodar (temozolomide) profile
Table 2.12: Tarceva (erlotinib) profile
Table 3.13: Top 10 future breakthrough cancer innovatives
Table 3.14: Future breakthrough cancer innovatives firsts…
Table 3.15: Alimta (pemetrexed) profile
Table 3.16: Gardasil (human papillomavirus vaccine) profile
Table 3.17: Sutent (sunitinib) profile
Table 3.18: Abraxane (paclitaxel) profile
Table 3.19: Nexavar (sorafenib) profile
Table 3.20: Vectibix (panitumumab) profile
Table 3.21: Sprycel (dasatinib) profile
Table 3.22: Tykerb (lapatinib) profile
Table 3.23: Cervarix (human papillomavirus vaccine) profile
Table 3.24: MDX-010 (ipilimumab) profile
Table 4.25: Leading cancer innovatives companies, 2003-2006
Table 4.26: Genentech’s cancer innovatives profile
Table 4.27: Genentech’s cancer innovatives profile (continued)
Table 4.28: Roche’s cancer innovatives profile
Table 4.29: Roche’s cancer innovatives profile (continued)
Table 4.30: Novartis’s cancer innovatives profile
Table 4.31: Novartis’s cancer innovatives profile (continued)
Table 4.32: Pfizer’s cancer innovatives profile
Table 4.33: Pfizer’s cancer innovatives profile (continued)
Table 4.34: Bristol-Myers Squibb’s cancer innovatives profile
Table 4.35: Sanofi-Aventis’s cancer innovatives profile
Table 4.36: Sanofi-Aventis’s cancer innovatives profile (continued)
Table 4.37: Schering-Plough’s cancer innovatives profile
Table 4.38: Eli Lilly’s cancer innovatives profile
Table 4.39: Merck’s cancer innovatives profile
Table 4.40: Bayer Schering’s cancer innovatives profile
Table 4.41: Amgen’s cancer innovatives profile
Table 4.42: GlaxoSmithKline’s cancer innovatives profile